We Update you with the Clock Running. Health Care News, Disease, Diagnose, Physicians, Residents, Medical Officers, Nursing Care, Technical Staff, Health Policies, Organizations, Certification, Standards, Alerts, and All about Worlds Health. Step to Facilitate the Health Care Professionals and Patients. Provide Safety and Quality to Patient's, Health Care staff, Explains Patient Family Education and Rights.
FDA Approves Orencia(R) (abatacept) For Moderate-To-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) In Patients Over Six
Arthritis Bristol-Myers Squibb Company (NYSE: BMY)today announced that the U.S. Food and Drug Administration (FDA) has approved ORENCIA® (abatacept) for reducing signs and symptoms in pediatric patients six years and older with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA). ORENCIA may be used as monotherapy or concomitantly with methotrexate (MTX).
Custom Search
